USSTOCK.TODAY
Pre-Market
Log in Sign up

Merck and Isomorphic Labs to Collaborate on AI-Driven Cancer Drug Discovery

Nasdaq +1 · ·by G4L

MRK Merck & Co Inc
$137.78 -3.90%
View chart & analysis →
  1. 1Merck has launched a research collaboration with Isomorphic Labs to discover small molecule cancer treatments using artificial intelligence.
  2. 2Isomorphic Labs will perform molecular design by applying its proprietary AI drug design engine, IsoDDE.
  3. 3Founded in 2021, Isomorphic Labs will handle computation-based drug discovery, while Merck will be responsible for subsequent development and commercialization.

So what's the key point?

Merck has started research to create cancer treatments alongside Isomorphic Labs, a company with artificial intelligence technology. Isomorphic Labs uses AI to design the drugs, and Merck will take on the role of developing and selling them.

Source Nasdaq +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →